Drugs / Intravenous immunoglobulin
Intravenous immunoglobulin
also known as
IVIG · Intravenous Immunoglobulin G · Gammagard · Gamunex · Gamunex-C · immune globulin intravenous \[human\] · ImmunoRel · NPB-01 · +2 more
Trials 40
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03130517 | Jul 2017 → Dec 2018 | anemia, nonspherocytic hemolytic | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT00176059 | Oct 2001 → May 2006 | chronic renal failure syndrome | University of Giessen | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07193953 | Apr 2025 → Nov 2026 expected | amyotrophic lateral sclerosis | Sunnybrook Health Sciences Centre | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04035135 | Jan 2020 → May 2021 | Guillain-Barre syndrome | Annexon, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00659386 | Feb 2009 → Feb 2010 | heart failure | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01594424 | Jun 2012 → Nov 2014 | end stage renal failure | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 213 trials · 1 missed | ||||||
| Phase 2 | NCT07674745 | Oct 2026 → Sep 2030 expected | idiopathic pulmonary fibrosis | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07698080 | Jul 2026 → Jul 2028 expected | aplastic anemia, leukemia, lymphoma, myelodysplastic syndrome +1 | Hematology department of the 920th hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03286556 | Sep 2018 → Aug 2024 | idiopathic pulmonary fibrosis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03401073 | Sep 2018 → Feb 2022 | neuropathy, small fiber | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03018652 | Mar 2018 → Nov 2019 | chronic obstructive pulmonary disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02690038 | Sep 2016 → Nov 2019 | chronic obstructive pulmonary disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02637700 | Jul 2016 → Mar 2019 | neuropathy, small fiber | Maastricht University Medical Center | Completed | Missed primary |
| Phase 2 | NCT00850005 | Feb 2009 → Jul 2010 | neuropathy, painful | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT00750867 | Jun 2008 → Sep 2009 | multiple system atrophy | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT00483119 | Apr 2007 → Feb 2010 | pemphigus vulgaris | NYU Langone Health | Terminated | No outcome recorded |
| Phase 2 | NCT00299988 | Feb 2006 → Jan 2009 | Alzheimer disease | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 2 | NCT00034242 | Apr 2002 → Feb 2004 | cerebellar degeneration | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00001287 | Dec 1990 → Jan 2001 | demyelinating polyneuropathy, monoclonal paraproteinemia disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07202052 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05134792 | Oct 2021 → Jul 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT04261426 | Feb → Apr 2020 | COVID-19 | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 39 trials · 2 missed | ||||||
| Phase 3 | NCT07299695 | Jan 2026 → Jun 2028 expected | idiopathic pulmonary fibrosis | Argyrios Tzouvelekis | Recruiting | No outcome recorded |
| Phase 3 | NCT07231523 | Dec 2025 → Jun 2027 expected | AChR+ myasthenia gravis | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05325008 | Aug 2023 → Aug 2027 expected | BK-virus nephropathy, chronic transplant rejection, polyomavirus infectious disease | The University of Queensland | Recruiting | No outcome recorded |
| Phase 3 | NCT05422365 | Jul 2022 → Dec 2023 | primary thrombocytopenia | Biopharma Plasma LLC | Completed | No outcome recorded |
| Phase 3 | NCT03351569 | Dec 2015 → Dec 2016 | Unverricht-Lundborg syndrome | Azienda Socio Sanitaria Territoriale di Mantova | Unknown | No outcome recorded |
| Phase 3 | NCT01696500 | Oct 2012 → Jun 2014 | Stevens-Johnson syndrome | Nihon Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00722475 | Aug 2008 → May 2014 | pregnancy loss, recurrent, 4 | Rigshospitalet, Denmark | Completed | Missed primary |
| Phase 3 | NCT00348296 | Jul 2006 → Jul 2009 | systemic sclerosis | Benesis Corporation | Completed | Missed primary |
| Phase 3 | NCT00001768 | Oct 1997 → Jun 2000 | autoimmune disease, schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06183008 | Feb 2024 → Dec 2028 expected | idiopathic small fibers neuropathy, neuropathy, painful | Sorlandet Hospital HF | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05604859 | Aug 2022 → Dec 2023 | — | Qin Ning | Unknown | No outcome recorded |
| Phase 4 | NCT02695797 | Sep 2015 → Dec 2016 | epilepsy | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02372149 | Feb 2015 → Feb 2018 | diabetes mellitus, peripheral neuropathy, polyneuropathy, inflammatory demyelinating, chronic | University of Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT01561755 | Feb 2012 → Sep 2016 | tropical spastic paraparesis | David M. Simpson | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable4 trials | ||||||
| — | NCT07068126 | Jan → Dec 2025 overdue | autoimmune thrombocytopenia | Assiut University | Recruiting | No outcome recorded |
| — | NCT07532707 | Sep 2022 → Oct 2023 | myasthenia gravis | Damascus University | Completed | No outcome recorded |
| — | NCT00511212 | Aug 2007 → Jun 2009 | peritonitis | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group | Withdrawn | No outcome recorded |
| — | NCT00615797 | May 2002 → Dec 2009 | Sydenham chorea, post-bacterial disorder | University of Cape Town | Completed | No outcome recorded |
| Comparator or background therapy21 trials | ||||||
| Phase 1 | NCT06753955 Background | Feb → Jul 2025 | anti-NMDA receptor encephalitis, autoimmune encephalitis | Arialys Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02586051 Background | Nov 2015 → Nov 2018 | end stage renal failure | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00271570 Comparator | Apr 2004 → Oct 2006 | Kawasaki disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT05634824 Comparator | Jan 2023 | autoimmune thrombocytopenia, pregnancy disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05156710 Background | Jun 2022 → Oct 2025 overdue | transplant rejection | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04728425 Comparator | Aug 2020 → Jun 2023 | myasthenia gravis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT03630211 Background | Jul 2018 → Aug 2026 overdue | diffuse scleroderma, interstitial lung disease, pulmonary hypertension | Paul Szabolcs | Recruiting | No outcome recorded |
| Phase 2 | NCT03194815 Comparator | Nov 2017 → Apr 2027 expected | autoimmune encephalitis, psychotic disorder | University of Cambridge | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01856205 Comparator | May → Aug 2009 | Japanese encephalitis | University of Liverpool | Completed | No outcome recorded |
| Phase 2 | NCT00230035 Comparator | Sep 2005 → ? | systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT05104762 Comparator | Sep 2021 → Mar 2022 | Guillain-Barre syndrome | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02205762 Background | Nov 2016 → Jul 2026 overdue | Langerhans cell histiocytosis | North American Consortium for Histiocytosis | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06867991 Comparator | Nov 2024 → Nov 2026 expected | anti-NMDA receptor encephalitis | The First People's Hospital of Changzhou | Recruiting | No outcome recorded |
| Phase 3 | NCT04656184 Comparator | Oct 2023 → Mar 2027 expected | Kawasaki disease | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05494619 Background | Nov 2022 → Mar 2026 | Guillain-Barre syndrome | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT03994783 Background | Jul 2019 → Jul 2021 | transplant rejection | Imperial College London | Terminated | No outcome recorded |
| Phase 3 | NCT02697292 Comparator | Feb 2016 → Dec 2018 | autoimmune epilepsy | Mayo Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT00892112 Comparator | Nov 2009 → Jun 2018 | Parvoviridae infectious disease, cardiomyopathy | Prothya Biosolutions | Completed | No outcome recorded |
| — | NCT05114941 Comparator | Jan → Dec 2026 expected | Guillain-Barre syndrome | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| — | NCT02449746 Comparator | Aug 2015 → Aug 2017 | autoimmune disease, schizophrenia | University of Cambridge | Completed | No outcome recorded |
| — | NCT01617317 Comparator | Jan 2010 → Nov 2011 | swine influenza | The University of Hong Kong | Completed | No outcome recorded |
Press releases naming this drug 13 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 63 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous immunoglobulin | “Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated,...” NCT07068126 ↗60“Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19” NCT03286556 ↗ “Intravenous immunoglobulin (IVIG) and oral prednisolone.” NCT02695797 ↗ “Intravenous Immunoglobulin” NCT07231523 ↗ “Intravenous Immunoglobulin” NCT02586051 ↗ |
| Known as | Gammagard | “A Placebo-controlled, Randomized, Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin (IVIg) for Treatment of Mild to Moderate Alzheimer's Disease” NCT00299988 ↗ |
| Known as | Gamunex | “Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).” NCT00850005 ↗ |
| Known as | Gamunex-C | “Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.” NCT03401073 ↗ |
| Known as | immune globulin intravenous \[human\] | “Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).” NCT00850005 ↗ |
| Known as | ImmunoRel | “Children received either saline or intravenous immunoglobulin (IVIG) \[ImmunoRel™ (batch 20081217)\] at a dose of 400mg/kg/day for 5 days” NCT01856205 ↗ |
| Known as | Intravenous Immunoglobulin G | “Intravenous Immunoglobulin G (IVIG) therapy has been widely used for a variety of indications in newborn period such as alloimmune neonatal thrombocytopenia and an adjunctive...” NCT03130517 ↗1“Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous \[human\], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).” NCT00850005 ↗ |
| Known as | IVIG | “This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the...” NCT07231523 ↗30“Intravenous Immunoglobulin G (IVIG) therapy has been widely used for a variety of indications in newborn period such as alloimmune neonatal thrombocytopenia and an adjunctive...” NCT03130517 ↗ “Intravenous Immunoglobulin IVIg is a medication that has been used to treat diseases like Kawasaki disease, systemic juvenile rheumatoid arthritis, lupus nephritis, and...” NCT00001768 ↗ “intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was...” NCT05604859 ↗ “We hypothesise, that the use of intravenous immunoglobulins ( IVIG) will decrease the number of circulating antibodies thereby decreasing symptom severity and shortening the...” NCT00615797 ↗ “Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated,...” NCT07068126 ↗ “This study will examine whether high-dose intravenous immunoglobulin (IVIG) is safe and effective for treating cerebellar ataxia-degeneration of the cerebellum” NCT00034242 ↗ “Previous uncontrolled studies suggested a possible benefit of intravenous immunoglobulin (IVIg) in parvovirus B19 (B19V)-related dilated cardiomyopathy (DCM).” PMID 33347677 ↗ Jan 2021 “This study explores the effects of an immune-modulating blood-derived product, intravenous immunoglobulin (IVIG), in treating neuropathic pain.” NCT00850005 ↗ “Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.” NCT05494619 ↗ “group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.” NCT05104762 ↗ |
| Known as | NPB-01 | “Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days.” NCT01696500 ↗ |
| Known as | Privigen | “Privigen® IVIg comes in vials containing 10% active ingredient.” NCT07193953 ↗ |
| Known as | Venoglobulin-IH | “High-dose intravenous immunoglobulin (Venoglobulin-IH)” NCT00348296 ↗ |
| Action | Inhibit | “IVIg treatment will reduce the levels of beta amyloid in the brain” NCT00299988 ↗ |
| Modality | Protein / enzyme biologic | “IVIg contains antibodies against the amyloid beta protein” NCT00299988 ↗ |
| Route | Intravenous | “intravenous immunoglobulin (IVIg)” NCT00001287 ↗ |